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Neoadjuvant chemotherapy has become the standard of
treatment for patients with locally advanced breast cancer
and is now a potential treatment for patients with ear-
lier stage operable disease. Preoperative chemotherapy
allows more patients to be treated with breast-conserving
surgery and enables direct in vivo assessment of response,
which correlates with outcome. The role of imaging is to
evaluate the therapeutic response in term of shrinkage of
the tumour in order to safely perform breast-conservation
surgery. Neoadjuvant chemotherapy is also a good model
to determine which radiological procedure is the most
effective to predict histopathological response.
Although controversial, several articles reported that
physical examination correlates best with pathologic
findings in the measurement of the primary tumour.
Mammography allows monitoring changes in size and
density of the tumour, but cannot identify changes in the
inner structure. Ultrasound is the most accurate predictor
of size for axillary lymph nodes.
Physical examination associated with mammography
and ultrasound is a valuable non-invasive combination for
assessing tumour dimension. MRI is the best modality
for assessment of response in term of tumour size
and in the detection of multifocal or multicentric
disease. The study of residual tumour vascularity is
interesting as the diagnosis is based on the early contrast
enhancement. The disappearance of this early contrast
enhancement allows correct identification of the response
to chemotherapy, even if several studies have reported
false negative and false positive cases. Conversely, the
detection of a persistent wash out phenomenon in
residual tumour permits detection of non-responders.
Breast helical CT can be an alternative to breast MRI
for the measurement of residual tumour volume and
correlation with pathologic findings. Colour Doppler
ultrasound and the use of ultrasound contrast agents
have given conflicting results because of their operator-
dependence.
Other functional imaging modalities have been pro-
posed for the assessment of response to neoadjuvant
chemotherapy. Mammoscintigraphy using 99mTc ses-
tamibi, shows that a rapid clearance of the tracer can
predict the lack of tumour response to chemotherapy,
however a slower tracer clearance cannot certify an
objective response. Positron emission tomography using
18FDG shows significant difference in tracer uptake
between responding and non-responding tumours early in
the course of therapy. After the second chemotherapeutic
cycle, both techniques are able to distinguish between
complete, partial or no response. The disadvantage of the
18FDG PET is the cost of the technique and the problem
of access to the machines. It has also a limited spatial
resolution. Combined 18FDG PET and MRI provide
useful information because of the high spatial resolution
of MR imaging.
In conclusion, studying the effect of neoadjuvant
chemotherapy will demonstrate the accuracy of these
complementary functional imaging techniques.
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